The July 2026 PCAC Vote on KPV, Explained

KPV is short for the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It circulates in compounding and research-chemical channels as an injectable or topical preparation, marketed for inflammatory skin conditions and gut inflammation. It is not an FDA-approved drug, and it should not be confused with full-length alpha-MSH analogs like afamelanotide, which is approved for a different indication under a different regulatory pathway.

This page answers one narrow question: what did the July 2026 PCAC vote actually do, and what happens next. For dosing, condition-specific evidence, or comparisons to topical steroids, see the KPV pillar page, the KPV dosing guide, or the KPV for IBD and ulcerative colitis page.

What is PCAC and what does it actually do?

The Pharmacy Compounding Advisory Committee is an FDA advisory body. It reviews candidate bulk drug substances, hears public and industry testimony, and votes to recommend or not recommend that a substance be added to (or kept off) the 503A bulks list under section 503A of the FD&C Act. PCAC does not have rulemaking authority. Its votes are advice to the agency. FDA and HHS decide, separately and later, whether to act on that advice, and they are not obligated to follow it.

The 503A list matters because compounding pharmacies can only legally compound a drug from a bulk substance if that substance is FDA-approved, is the subject of an applicable USP/NF monograph, or appears on the 503A bulks list. KPV is none of these as of September 2026. The framework for how a substance gets onto that list is described directly by FDA: Bulk Drug Substances Used in Compounding Under Section 503A.

What did the July 2026 vote decide, in plain terms?

At the July 23-24, 2026 meeting, PCAC voted 8 yes, 6 no, 1 abstain to recommend that KPV be added to the 503A list. Meeting details are published on FDA's own calendar page: July 23-24, 2026 PCAC meeting.

A close, split vote like 8-6-1 signals real disagreement among committee members about the strength of the safety and clinical-need case for KPV. It is worth reading the vote as evidence that the agency's own reviewers were not unanimous, not as a signal that approval is imminent or routine.

What the vote does not do:

• It does not add KPV to the 503A bulks list. That requires separate FDA/HHS action, which has a rulemaking-adjacent process and no announced deadline.
• It does not make KPV FDA-approved for any indication. Approval and 503A bulk-listing are different regulatory tracks; neither implies the other.
• It does not create or extend any enforcement discretion for compounding KPV in the interim. Compounding it now sits outside the 503A framework entirely.
• It does not resolve or reference KPV's earlier history in FDA's Category 2 nomination list for bulk substances that may present significant safety risks. That nomination was withdrawn by the nominators, and KPV is no longer categorized there, but withdrawal of a safety-risk nomination is not the same action as an approval or a bulks-list addition. See FDA's Category 2 substances page for the current list: Certain Bulk Drug Substances That May Present Significant Safety Risks.

Is KPV legal to compound right now?

No, not under the 503A bulk-substance pathway. As of September 2026, KPV is not FDA-approved, is not the subject of an applicable compendial monograph that would qualify it, and is not on the 503A bulks list. The PCAC recommendation changes none of that status on its own. A pharmacy compounding KPV today is doing so outside the framework that section 503A sets up for bulk substances, regardless of the committee's vote.

This is a genuinely confusing point because "no longer in Category 2" sounds like clearance. It is not. Category 2 is a list of substances FDA has flagged as presenting significant safety risks in compounding; being removed from that list only means the safety-risk nomination was withdrawn, not that the substance has cleared any approval or listing bar. Two different questions, two different lists, and neither one currently answers "is this legal to compound."

What has to happen before KPV could legally appear in compounded products?

The three-gate test for any bulk-substance compounding decision

Before treating a compounded peptide as available and appropriate to prescribe or use, check all three gates. KPV currently fails at least two.

Passing gate 3 (no safety flag) only removes one obstacle. Gates 1 and 2 still have to clear before compounding under 503A is on solid regulatory footing. A prescriber or patient who sees "PCAC recommended it" or "not on the safety-risk list anymore" and concludes KPV is now fine to compound is skipping gates 1 and 2 entirely. That is the error this vote is likely to cause if reported loosely.

Realistic next steps, based on how FDA has handled other 503A bulk-substance recommendations: FDA reviews the committee's vote and testimony, may request additional data (stability, sourcing, quality specifications), and eventually publishes a decision, which can affirm, reject, or defer the recommendation. There is no fixed statutory clock for this step, and prior 503A additions have taken anywhere from several months to multiple years after a favorable committee vote. Anyone telling a patient "KPV compounding will be legal by [specific date]" is stating something FDA has not committed to.

What does the underlying evidence for KPV actually look like?

Separate from the regulatory question, it is worth being honest about what supports KPV's proposed uses. The tripeptide has been studied mainly in cell culture and animal models: reduced cytokine signaling and colitis severity in mice (Gastroenterology, 2008; Inflammatory Bowel Diseases, 2008), anti-inflammatory activity in bronchial epithelial cells (International Journal of Physiology, Pathophysiology and Pharmacology, 2012), and neuroprotective effects in a mouse traumatic brain injury model (PLoS One, 2013). Broader review of alpha-MSH-derived peptides as anti-inflammatory agents is summarized in the 2008 Endocrine Reviews paper. Human clinical trial data for KPV specifically are limited; the evidence base is preclinical and mechanistic rather than confirmatory in patients. A regulatory pathway existing (or not) does not itself validate or invalidate this underlying science, and vice versa. For a fuller condition-by-condition breakdown, see KPV for eczema and psoriasis and KPV compared with topical steroids.

Established, plausible, and not established

Established: PCAC voted 8-6-1 in July 2026 to recommend KPV for the 503A bulks list; KPV's Category 2 nomination was withdrawn; KPV is not FDA-approved and not currently on the 503A list.

Plausible but unproven: that FDA will eventually add KPV to the 503A list, given the committee's recommendation; that this would meaningfully expand legitimate compounding access if it happens.

Not established: any timeline for FDA action, any guarantee that FDA will follow the recommendation, and any claim that KPV compounding is currently authorized or "in process" of becoming legal. Readers or clinicians considering KPV, whether topical or systemic, should treat its regulatory status as unresolved and verify current listing status directly against FDA's published pages before assuming otherwise.

If a source, product label, or clinic tells you KPV is "FDA-cleared for compounding" based on this vote, that claim is not accurate as of September 2026 and is worth asking about directly.